Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer
Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.
Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.
There is a need for better endocrine agents and an interest in novel SERD drugs like RAD1901 that can bind to the estrogen receptor and potentially degrade it, says Bardia. These type of agents may fill a gap where, currently, there are not great therapies available, particularly for the treatment of tumors with ESR1 mutations, he says.
RAD1901 was evaluated for safety and tolerability in patients with ER-positive metastatic breast cancer in a phase I trial.
The major adverse events seen were nausea and dyspepsia, says Bardia. The trial will now enroll additional patients at higher doses and then continue on to a larger dose expansion or phase II trial. EndFragment
